LLS Phone Education Programs for June: "NHL: Diagnosis/Treatment Decisions"

This June, as part of the Leukemia & Lymphoma Society's ongoing Lymphoma Education Series, the LLS is offering three FREE telephone education programs. The third of those programs is below.

In order to participate, you need only to register. These are free, 90 minute programs hosted by lymphoma experts and followed by Q&A sessions in which you can ask questions. You don't need to go anywhere to participate, you don't need to pay anything, you just need to call in at the proper time.

Program: NHL: Understanding Diagnosis and Making Treatment Decisions

About: Learn about tests, treatments, emerging therapies, and clinical trials for non-Hodgkin lymphoma
When: Wednesday June 24, 2009 at 12 noon (eastern time)

Hosted by:
Steven H. Bernstein, MD
Professor of Medicine
Co-Director, Lymphoma Biology Program
James P. Wilmot Cancer Center
University of Rochester Medical Center
Rochester, NY

Click HERE for the program's main information page, and to access the registration page.

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap